RxDoctor Payments Data

Lorenzo Rossaro, MD

Gastroenterology · Woodland, CANPI 1750368163

Payments from drug & device makers

$184,693in general payments, 2019–2025

Across 226 payments — averaging $817.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$124K
  • AbbVie$49K
  • Intra-sana Laboratories$6K
  • Ipsen Biopharmaceuticals, Inc$3K
  • Gilead$809
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$498
  • plus $821 from 9 others

What the payments were for

  • Consulting fees$2,4801%
  • Speaking & faculty fees$161,02087%
  • Travel & lodging$12,9827%
  • Food & beverage$8,2114%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$184,693 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$78,103
Medicare patients
310
Services billed
617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin114$400,389
VemlidyTenofovir Alafenamide22$37,249
Ursodiol85$23,686
Tacrolimus70$7,865
Entecavir22$5,290
Lactulose88$3,117
Spironolactone127$1,783
Omeprazole33$603
Carvedilol60$515
Pantoprazole Sodium38$472
Furosemide111$432
Famotidine15$266
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl14$174
Hydroxyzine Hcl14$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$498$400,389114 claims
GileadVemlidy$809$37,24922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Woodland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →